Skip to content
cccskills
FreePublished on GitHub

es-cushing-testing-for-recurrence-lifelong-except-low-ct-density

This skill recommends lifelong biochemical testing for recurrence in all patients with Cushing's syndrome after adrenalectomy, except those with resected adrenal adenoma showing CT density <10 Hounsfield units. Use when determining long‑term follow‑up strategy for a post‑adrenalectomy CS patient; triggers include “post‑adrenalectomy Cushing’s syndrome”, “CT density <10 HU”, and “adrenal adenoma resection”.

The English summary is being prepared. Showing the original description.

See how to install

Files included (1)

  • SKILL.md3.4 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Testing for Recurrence Throughout Life Except in Patients Who Underwent Resection of Adrenal Adenoma with CT Density <10 Hounsfield Units

STEP 1 — Gather Information

Collect operative report, pathology confirming adrenal adenoma, non‑contrast CT Hounsfield units of the resected lesion, postoperative biochemical remission status (morning cortisol <5 µg/dL and normal late‑night salivary cortisol or urine free cortisol), and baseline comorbidity assessment. Then proceed to assess the CT density threshold.

STEP 2 — Rule In / Rule Out

If the resected adrenal adenoma has a CT density <10 HU and pathology confirms a benign adenoma, rule out the need for lifelong biochemical recurrence testing; otherwise rule in the need for lifelong testing. End decision: skip lifelong testing for low‑density adenoma or move to classification for all others.

STEP 3 — Classify or Stratify

For patients ruled in for lifelong testing, confirm postoperative eucortisolism (morning cortisol <5 µg/dL and normal late‑night salivary cortisol). If eucortisolism is confirmed, proceed to schedule surveillance; if not, manage persistent hypercortisolism per guideline. End decision: confirm remission status to direct surveillance or treat persistent disease.

STEP 4 — Decide

For patients with confirmed eucortisolism, schedule late‑night salivary cortisol or urine free cortisol every 6–12 months indefinitely and continue routine comorbidity monitoring; for patients with persistent hypercortisolism, initiate appropriate treatment (medical, surgical, or radiation) according to the guideline. End decision: implement lifelong surveillance plan or active treatment.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on symptoms alone to exclude recurrence; ensure CT measurement is performed on non‑contrast scans and that the value truly reflects the adenoma (avoid confusing hyperplasia or carcinoma). A single normal test does not guarantee permanent cure; lifelong periodic testing is required unless the low‑density adenoma criterion is met. Misclassifying an adrenal carcinoma as an adenoma with low CT density can lead to inadequate follow‑up.

Concrete Clinical Example

A 48‑year‑old woman underwent left adrenalectomy for a 2.5 cm adenoma; postoperative pathology showed benign adenoma, non‑contrast CT density was 8 HU, and morning cortisol and late‑night salivary cortisol were normal. According to this skill, she does not require lifelong biochemical testing for Cushing’s recurrence, only standard monitoring of hypertension, diabetes, and osteoporosis.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, https://doi.org/10.1210/jc.2015-1818

TODO: consider adding scripts/calc.py for the es-cushing-testing-for-recurrence-lifelong-except-low-ct-density calculator

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill